Collagenase Clostridium Histolyticum: A Minimally Invasive Breakthrough in Fibrotic Disorders Introduction Fibrotic disorders like Dupuytren’s contracture and Peyronie’s disease significantly impact quality of life. Collagenase Clostridium histolyticum (CCH), an enzyme-based therapy, offers a non-surgical solution by breaking down excess collagen buildup in affected tissues. https://www.marketresearchfuture.com/reports/collagenase-clostridium-histolyticum-market-35828 What is Collagenase Clostridium histolyticum? CCH is a purified enzyme blend derived from Clostridium histolyticum bacteria. It specifically targets and hydrolyzes collagen types I and III, which are abundant in fibrotic tissues. Mechanism of Action Once injected into the fibrotic cord or plaque, CCH enzymatically cleaves collagen fibers, weakening the structure and enabling manual manipulation to restore normal tissue flexibility. FDA-Approved Indications Dupuytren’s Contracture – Approved in 2010 for adults with a palpable cord. Peyronie’s Disease – Approved in 2013 for adult men with curvature deformity. Advantages Over Surgery Minimally invasive with faster recovery Lower risk of complications compared to open surgery Can be performed in an outpatient setting Treatment Procedure Injection Phase – CCH is injected directly into the target site. Manipulation Phase – After 24–72 hours, the tissue is manually stretched or manipulated to break the cord or plaque. Rehabilitation – Includes splinting, stretching exercises, and follow-up visits. Safety Profile Common side effects include localized swelling, bruising, and pain. Rarely, tendon rupture or severe allergic reactions may occur. Market Insights The global market for CCH is growing, with increasing adoption due to patient demand for non-surgical alternatives. Strategic marketing by manufacturers and expanding awareness among physicians are driving uptake. Conclusion CCH has transformed the management of certain fibrotic disorders, offering an effective and less invasive treatment option. As research continues, expanded indications and improved formulations may further enhance its role in clinical practice.